Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways) - Trial NCT06221696

Timeline & Enrollment

Primary Outcome

Percentage of weight regain from baseline

Summary

This randomized, double-blind, placebo-controlled trial titled Preventing Weight Regain
 Post-Semaglutide Treatment with Active Fiber Supplement (Soloways) evaluated the efficacy of
 an active fiber supplement in preventing weight regain post-Semaglutide treatment.
 Participants were adults aged 18-65, with a history of obesity or overweight, and had
 completed a Semaglutide course. The study involved 160 participants, equally divided into two
 groups: one receiving the active fiber supplement (glucomannan, inulin, and psyllium) and the
 other a placebo, both taken 30 minutes before each main meal for 180 days. Co-primary
 endpoints were the percentage of weight regain from baseline to day 180 and metabolic health
 markers (blood glucose levels, HbA1c, lipid profile, blood pressure). Secondary endpoints
 included changes in BMI, body composition, and appetite assessment using VAS ratings and the
 Control of Eating Questionnaire (CoEQ). Participants also adhered to a reduced-calorie diet
 and increased physical activity, with all standard assays performed in a central laboratory.
 The study's objective was to determine the supplement's effectiveness in enhancing satiety,
 improving digestive health, and thus better managing weight compared to a placebo

ICD-10 Classifications